Galenica

Last updated
Galenica AG
Company type Corporation
SIX:  GALE
SMI MID component
ISIN CH0360674466
Industry Pharmacy, Healthcare, Logistics, Computer science (NACE 63), Retail
Founded1927
Headquarters
Bern
,
Switzerland
Key people
Daniela Bosshardt
(Chairwoman of the board of directors), Marc Werner
(CEO)
RevenueCHF 3'301 million (2019) [1]
Number of employees
7'071 (2019) [1]
Website www.galenica.com/en

Galenica AG, headquartered in Bern, is an internationally active Swiss pharmaceutical and logistics company group, named after the ancient physician Galenus. It dates back to the 1927 Collaboration Pharmaceutique SA, a purchasing center for pharmaceutical products founded by 16 pharmacists in Clarens. This was renamed to Galenica AG in 1932 and moved from Vaud's Le Châtelard to Bern. The Galenica shares are listed on the SIX Swiss Exchange and are a component of the SMI MID index.

Contents

History

Galenica was founded in 1827 by 16 West Swiss pharmacists. Their goal was to build a joint purchasing center. In 1938, Galenica laid the foundation for today's information management by establishment of the scientific documentation service, Documentation Galenica. Starting in 1957, the company diversified in its core business through acquisitions and formation of subsidiaries. In the same year, Galenica also laid the first cornerstone in the pharma business with the acquisition of Panpharma AG and the diversification into the sales promotion of parapharmaceutical articles for pharmacies. During the 1970s, other pharmaceutical acquisitions followed, contributing to the development and production of prescription-free drugs (OTC). In 1977, the Codex Galenica, the first complete list of medicines in Switzerland, was published in book form. In 1983, Galenica acquired the Hausmann AG laboratories, which also produced products for the treatment of iron deficiency, which were later marketed under the brand names Venofer and Maltofer. [2]

In 1999, they entered into a strategic partnership with the British-Swiss health group Alliance Boots, which took over 25% of Galenica shares. [3] [4]

In 2000, the founding of GaleniCare laid the cornerstone for the pharma chain and, [5] in 2001, all activities in the area of information processing were transferred to the newly founded company e-mediat. At the beginning of 2008, the acquisition of the Canadian pharmaceutical company Aspreva Pharmaceuticals formed the globally active, fully integrated and specialized Vifor Pharma.

Ownership changed in 2007 for the first time, when a consortium of private equity investor KKR and Stefano Pessina, took over Alliance Boots; the Galenica shares were then held by Alliance Boots Investments 2 GmbH. The second change took place in August 2014 through the acquisition of Alliance Boots by Walgreens, and with the merger to Walgreens Boots Alliance; the Galenica shares remained with KKR and Pessina, and were held by Sprint Investments 2 GmbH. The announced exit of financial investors began in May 2016 with the reduction of the shareholding to a good 20%, and the further complete reduction to be completed by 9 January 2017. [6]

Also in August 2014, Galenica was divided into the Vifor Pharma and Galenica Santé divisions. [7] The long-term objective was the split into two independent companies. [8] Galenica Santé's public offerings (IPO), which will be targeted by the end of 2017, are the main focus here. [6]

Since 7 April 2017, Galenica has been listed on the Swiss stock exchange as an independent company. To confirm the separation of the group into two independent companies, Galenica acquired the US biotech firm Relypsa for over $1.5 billion. [9] [10] Galenica's shares raised $1.9 billion during their debut on the stock market. [11]

In 2019, Galenica purchased the Berner-Bichsel-Group acquiring a majority stake. The group specializes in the manufacture of personalized medicines and homecare of patients. [12]

Subsidiary company

The Swiss pharmacy chains Amavita and Sun Store, among others, are also part of Galenica, which work together with Coop in the joint venture Coop Vitality Pharmacy. In drug production, it is present with its subsidiary Vifor Consumer Health and in logistics with Galexis AG and Alloga AG. [13]

Documed

Logo Logo documed.gif
Logo

Galenica also owns the publishing house Documed, founded in 1976. In 1978, this company started publishing the "Arzneimittelkompendiums", the drug compendium of Switzerland. Swissmedic required every pharmaceutical company to publish their drug information in Documed's compendium, giving Documed a monopoly that they defended with dubious means according to the "Tages-Anzeiger". After repeated criticism about this model, Swissmedic approved in 2008 the creation of the website oddb.org that would publish this information under an open data license. In response, Documed filed a lawsuit to prevent the operation of this site, which was decided by the Federal Administrative Court (Switzerland) in favour of the open source database. [14] As a result, Swissmedic was obliged to offer a way to access drug information free of charge on an Internet platform called AIPS. The tender for the construction and operation of this platform was won by an offer from Documed, which according to the "Tages-Anzeiger" was noticeably below that of the competitors.

e-mediat

Founded in 2001, the company is headquartered in Bern and offers services and databases for Swiss healthcare. [15]

Investigation of the Competition Commission

The Swiss Competition Commission (Weko) opened proceedings against the Galenica subsidiaries Documed, E-Mediat and HCI Solutions, [16] in 2012, since they were accused of abusing their market position. [17] Instead of publishing the drug information, Documed supposedly demanded money from E-Mediat, for the first time the release of the drug stem data in a database that they managed, which is used by hospitals to manage their medicine and settle accounts. Smaller pharmaceutical companies, in particular, were also asked to pay too much money. Several small businesses were threatened to remove their drugs from this database, which would have caused fatal consequences for these companies. After a group of 16 pharmaceutical companies decided to create a platform in cooperation with Just-medical and Ywesee, the companies offered discounts of up to 80 percent, when they signed two to four-year contracts. After the competition commission had initiated an investigation, Documed stopped their threats of removing drugs from the databases. [14]

Related Research Articles

<span class="mw-page-title-main">Alliance Healthcare</span> European health products distributor

Alliance Healthcare, formerly Alliance UniChem, is a wholesaler, distributor and retailer of pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres, and hospitals from over 288 distribution centres in 11 countries.

McKesson Europe

McKesson Europe AG, with its headquarters in Stuttgart, Germany, is a leading international wholesale and retail company and provider of logistics and services in the pharmaceutical and healthcare sectors. The company had around 37,000 employees at the end of the 2019 financial year and is represented in 13 countries in Europe. In the 2019 financial year the company achieved a turnover of EUR 21.18 billion. The majority shareholder of the company is the US-based McKesson Corporation, which holds a share of 77.01%. The remaining 22.99% of shares are available on the open market. Kevin Kettler, a US citizen, has been Chairman of McKesson Europe since 1 November 2018.

<span class="mw-page-title-main">Alliance Boots</span> Pharmaceutical company

Alliance Boots was a multinational pharmacy-led health and beauty group with corporate headquarters in Bern, Switzerland and operational headquarters in Nottingham and Weybridge, United Kingdom.

<span class="mw-page-title-main">Otsuka Pharmaceutical</span> Japanese pharmaceutical company

Otsuka Pharmaceutical Co., Ltd., abbreviated OPC, is a pharmaceutical company headquartered in Tokyo, Osaka and Naruto, Japan. The company was established August 10, 1964.

Ringier AG is a media group operating in multiple countries with over 6,500 employees. Founded in 1833, the family-owned business manages media brands across print and digital, TV and radio, and is active in the entertainment and digital marketplace sectors. The headquarters of Ringier AG is located in Zofingen, Aargau, with additional offices in Zurich and Lausanne.

Phoenix Pharmahandel GmbH & Co KG, headquartered in Mannheim, Baden-Württemberg, is the largest pharmaceutical wholesaler in Germany, and the second largest in Europe, with about 153 distribution centers across the country delivering drugs to approximately 12,000 independent pharmacies. Its Phoenix Documentation is an internet-based archive offering detailed information on drugs, their components, indications, and effects. The formation of holding company Phoenix International Beteiligungs GmbH took place. The Phoenix Group is a majority owner of the pharmaceutical wholesalers Purus A.S. in the Czech Republic and Tamro in Finland. The Phoenix Group itself is mostly owned by the pharmaceutical conglomerate Merckle Group.

<span class="mw-page-title-main">Stada Arzneimittel</span> German pharmaceutical company

Stada Arzneimittel AG is a pharmaceutical company based in Bad Vilbel, Germany which specializes on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In 2022, revenue totaled €3.79 billion.

Temmler Werke GmbH was founded in Detmold in 1917 by Hermann Temmler. The Temmler Group is a German pharmaceutical company, which focuses on the production, sale and contract production of pharmaceutical products. In 2012, the Temmler Group was taken over by the Aenova Group and with its seven production sites is one of the largest European pharmaceutical contract manufacturers.

<span class="mw-page-title-main">Evotec</span> German biopharmaceutical company

Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.

<span class="mw-page-title-main">Sunrise LLC</span> Swiss telecommunications company

Sunrise LLC, doing business as Sunrise, is a Swiss telecommunications provider based in Zurich. It provides mobile, TV and landline phone and internet services. Since February 2019, Sunrise headquarters are located at Thurgauerstrasse 101b, Glattpark Opfikon. Formerly a subsidiary of TDC A/S, Sunrise had been owned by CVC Capital Partners until 2015. In February 2015, CVC realised an IPO on the SIX Swiss Exchange. Since then, Sunrise stocks are publicly traded at the Swiss Stock Exchange. In August 2020, Liberty Global announced that it will be acquiring Sunrise for $7.4 billion. The transaction was completed on November 11, 2020. In November 2024, Liberty Global completed the spin-off of Sunrise, turning it into an independent public entity operating autonomously in the Swiss telecommunications market.

Dishman Carbogen Amcis Ltd is an Indian multinational pharmaceutical company specialized in the manufacture of active ingredients and contract development and manufacturing. Dishman employs over 1,000 people worldwide and is listed on the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE).

<span class="mw-page-title-main">Stefano Pessina</span> Italian billionaire businessman (born 1941)

Stefano Pessina is an Italian-Monegasque billionaire businessman; he is the executive chairman and largest single shareholder of Walgreens Boots Alliance.

Walgreens Boots Alliance, Inc. (WBA) is an American multinational holding company headquartered in Deerfield, Illinois, which owns the retail pharmacy chains Walgreens in the US and Boots in the UK, as well as several pharmaceutical manufacturing and distribution companies. The company was formed on December 31, 2014, after Walgreens bought the 55% stake in Alliance Boots that it did not already own. The total price of the acquisition was $4.9 billion in cash and 144.3 million common shares with fair value of $10.7 billion. Walgreens had previously purchased 45% of the company for $4.0 billion and 83.4 million common shares in August 2012 with an option to purchase the remaining shares within three years. Walgreens became a subsidiary of the newly created company after the transactions were completed. As of 2022, Walgreens Boots Alliance is ranked #18 on the Fortune 500 rankings of the largest United States corporations by total revenue.

David Ebsworth is non-executive chairman at Verona Pharma Plc. His career spans over 35 years in the global pharmaceutical industry, during which he was Global Head of Pharmaceuticals at Bayer AG and CEO of a number of companies, including ViforPharma and Galenica. He is also an advisor to a variety of CEOs at public and private organisations.

The Verband Forschender Arzneimittelhersteller (vfa) or Association of Research-Based Pharmaceutical Companies, is the trade group of 43 pharmaceutical companies in Germany which are global players, representing more than two-thirds of the German pharmaceutical market, with nearly 80,000 employees in Germany.

The SMI MID (SMIM) is a stock index which lists Switzerland's mid-cap companies. The index is calculated by SIX Swiss Exchange.

CSL Vifor is a global specialty pharmaceuticals company in the treatment areas of iron deficiency, dialysis, nephrology & rare disease. It is headquartered in Switzerland and consists of CSL Vifor, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Sanifit Therapeutics.

Etienne Jean Jornod is a Swiss entrepreneur and manager. He was Chairman of the Board of Directors of the pharmaceutical and logistics group Galenica and the NZZ Mediengruppe.

<span class="mw-page-title-main">Jean-Christophe Leroux</span>

Dr. Jean-Christophe Leroux is a French-Canadian full professor of Drug Formulation and Delivery at the Institute of Pharmaceutical Sciences at the Swiss Federal Institute of Technology ETH Zürich. His research is mainly focused on broadening the field of drug delivery, and the development of biodetoxification systems for the treatment of metabolite disorders. Additionally, he has made important contributions to the field of biomaterials for use in drug delivery.

<span class="mw-page-title-main">Schott Pharma</span> Company carved out from Schott AG in 2022, stock listed in SDAX

Schott Pharma is a provider of drug containment solutions and delivery systems for injectable drugs. Originally a division of glass manufacturer Schott AG, the company went public on the Frankfurt Stock Exchange in 2023. Headquartered in Mainz, Germany, the company operates in 14 countries.

References

  1. 1 2 "Annual report 2019" (PDF). Galenica. Retrieved 5 January 2021.
  2. ↑ Christoph Zürcher (24 October 2006). "Galenica". Historisches Lexikon der Schweiz. Retrieved 30 October 2017.
  3. ↑ "Sprint Investments 2 nicht mehr an der Galenica Gruppe beteiligt". lifePR. Retrieved 24 December 2020.
  4. ↑ "Galenica-Grossaktionär Sprint hat Beteiligung vollständig abgestossen". Market Screener. 9 January 2017. Retrieved 24 December 2020.
  5. ↑ "Geschäftsbericht 2012" (PDF). Galenica. Retrieved 4 January 2021.
  6. 1 2 "Galenica:Grossaktionär plant Ausstieg". Handelszeitung. 9 August 2016. Retrieved 30 October 2017.
  7. ↑ Juliane Lutz (13 August 2014). "Galenica verschreibt sich eine Aufspaltung". Berner Zeitung . Retrieved 30 October 2017.
  8. ↑ "Eine Gruppe, zwei Strategien und die Vision, zwei unabhängige an der Börse kotierte Unternehmen zu schaffen" (PDF). Galenica. 2014. Retrieved 30 October 2017.
  9. ↑ "All change at Galenica with split, IPO and name change". www.thepharmaletter.com. Retrieved 2020-04-29.
  10. ↑ "Galenica Group focuses on pharmaceuticals as it becomes Vifor Pharma Group". News-Medical.net. 2017-04-07. Retrieved 2020-04-29.
  11. ↑ "Galenica Sante raises $1.9 billion in Europe's biggest IPO this year". Reuters. 2017-04-07. Retrieved 2020-04-29.
  12. ↑ "Galenica kauft die Berner Bichsel-Gruppe". Ringier Axel Springer Schweiz. 30 April 2019. Retrieved 4 January 2021.
  13. ↑ "Umsatz der Vifor Consumer Health AG". Statista. Retrieved 5 January 2021.
  14. 1 2 Andreas Möckli (13 December 2012). "Die zweifelhaften Methoden der Galenica-Tochter Documed". Tages Anzeiger. Retrieved 30 October 2017.
  15. ↑ "Galenica". Die Chemie Schule. Retrieved 5 January 2021.
  16. ↑ "HCI Solutions". HCI Solutions. Retrieved 30 October 2017.
  17. ↑ "Die WEKO eröffnet eine Untersuchung betreffend die Kommerzialisierung von Medikamenteninformationen" (PDF). Medienmitteilung der WEKO. 12 December 2012. Retrieved 30 October 2017.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.